European Union - English - EMA (European Medicines Agency)

biogen netherlands b.v. - dimethyl fumarate - multiple sclerosis - immunosuppressants - tecfidera is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (rrms).

European Union - English - EMA (European Medicines Agency)

biogen netherlands b.v. - peginterferon beta-1a - multiple sclerosis - immunostimulants, - treatment of relapsing remitting multiple sclerosis in adult patients.

European Union - English - EMA (European Medicines Agency)

biogen netherlands b.v. - natalizumab - multiple sclerosis - selective immunosuppressants - tysabri is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups: , patients with highly active disease activity despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4.4 and 5.1), , or, patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.

European Union - English - EMA (European Medicines Agency)

biogen netherlands b.v. - diroximel fumarate (biib098) - multiple sclerosis, relapsing-remitting - immunosuppressants - vumerity is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (see section 5.1 for important information on the populations for which efficacy has been established).

European Union - English - EMA (European Medicines Agency)

biogen netherlands b.v.  - interferon beta-1a - multiple sclerosis - immunostimulants, - avonex is indicated for the treatment of:patients diagnosed with relapsing multiple sclerosis (ms). in clinical trials, this was characterised by two or more acute exacerbations (relapses) in the previous three years without evidence of continuous progression between relapses; avonex slows the progression of disability and decreases the frequency of relapses;patients with a single demyelinating event with an active inflammatory process, if it is severe enough to warrant treatment with intravenous corticosteroids, if alternative diagnoses have been excluded, and if they are determined to be at high risk of developing clinically definite ms.avonex should be discontinued in patients who develop progressive ms.

United States - English - NLM (National Library of Medicine)

therabiogen - green tea leaf (unii: w2zu1ry8b0) (green tea leaf - unii:w2zu1ry8b0), sambucus nigra flowering top (unii: ct03bsa18u) (sambucus nigra flowering top - unii:ct03bsa18u), gelsemium sempervirens root (unii: 639kr60q1q) (gelsemium sempervirens root - unii:639kr60q1q), bryonia alba root (unii: t7j046yi2b) (bryonia alba root - unii:t7j046yi2b), sulfur (unii: 70fd1kfu70) (sulfur - unii:70fd1kfu70) - green tea leaf 3 [hp_x] in 15 ml - purpose cold and flu symptom relief uses relieves old and flu symptoms provides relief from upper respiratory symptoms such as nasal and sinus congestion, runny nose, sore throat, sneezing and headache also relieves fever, chills and body aches associated with the flu stop use and ask a doctor if symptoms persist

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

probiogenics (m) sdn bhd - lactobacillus rhamnosus; inulin; bifidobacterium longum; streptococcus thermophilus; lactobacillus plantarum; lactobacillus casei; bifidobacterium lactis; bifidobacterium infantis; lactobacillus acidophilus. -

European Union - English - EMA (European Medicines Agency)

biogen netherlands b.v. - nusinersen sodium - muscular atrophy, spinal - other nervous system drugs - spinraza is indicated for the treatment of 5q spinal muscular atrophy.

European Union - English - EMA (European Medicines Agency)

biogen netherlands b.v.  - fampridine - multiple sclerosis - other nervous system drugs - fampyra is indicated for the improvement of walking in adult patients with multiple sclerosis with walking disability (expanded disability status scale 4-7).

New Zealand - English - Medsafe (Medicines Safety Authority)

biogen nz biopharma ltd - peginterferon beta-1a 94ug;  ; peginterferon beta-1a 63ug - solution for injection - active: peginterferon beta-1a 94ug   excipient: arginine hydrochloride glacial acetic acid polysorbate 20 sodium acetate trihydrate water for injection active: peginterferon beta-1a 63ug excipient: arginine hydrochloride glacial acetic acid polysorbate 20 sodium acetate trihydrate water for injection - plegridy is indicated for the treatment of relapsing forms of multiple sclerosis